Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
High-dose online hemodiafiltration (HDF) has shown survival advantages over conventional hemodialysis (HD) in randomized and real-world settings. Evidence in large insured cohorts from emerging health systems remains limited. We evaluated the impact of HDF on all-cause mortality versus HD (HDI) across ~100 clinics in Brazil.
We performed a retrospective cohort study using a national mortality dashboard from 100 DaVita Brazil clinics. All adult, privately insured patients receiving maintenance HDI or HDF between January 2024 and August 2025 (20 months) were included. For each modality we calculated: mean patients/month, mean deaths/month, and monthly mortality (deaths ÷ patients). Exposure was expressed as patient-months (mean census × 20). We also summarized age, CKD etiology, comorbidities, and causes of death using standardized dashboard categories.
Primary endpoint: mortality rate ratio (RR) for HDF vs HDI with 95% CI (log method). Hypothesis testing used a two-sided z-test for equality of proportions with denominators in patient-months. Significance: p<0.05. We report monthly estimates and, for clinical context, annualized risk (1 – (1 – monthly rate)12^{12}12) and absolute risk reduction (ARR)/number needed to treat (NNT).
All insured patients: 5,711 patients/month; 73 deaths/month; monthly mortality 1.28%. HDI: 2,862 patients/month (~57,240 patient-months); 42 deaths/month (~840 deaths); mortality 1.47%.
HDF: 2,330 patients/month (46,600 patient-months); 26 deaths/month (520 deaths); mortality 1.12%.
Primary comparison: RR (HDF vs HDI) = 0.76 (95% CI 0.68–0.85); z = −4.96; p p<0.001.
Annualized risk (contextual): HDI ≈ 17.1%, HDF ≈ 12.7% → ARR 4.4%, relative reduction ≈26%, NNT ≈23 patients/year to avert one death (derived from annualized risks).
Population profile (HDF): 60–79 y 53.1%, ≥80 y 28.1%; leading etiologies diabetes ~31%, hypertension ~25%; common comorbidities primary hypertension 25%, heart failure 10%; causes of death other/unknown ~40%, cardiovascular ~15%, infection ~11%.
Across 100 clinics and 20 months, HDF demonstrated significantly lower monthly mortality than HDI (1.12% vs 1.47%; RR 0.76; p<0.001). Annualized estimates correspond to an ARR of ~4–5% and NNT ≈23, supporting broader deployment of high-dose HDF in insured Brazilian populations. Future work should adjust for comorbidity, vascular access and dialysis vintage, incorporate frailty and PROMs, and assess cost-effectiveness to guide policy and scale-up.
